The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis

David Maussang, Camilla De Nardis, Linda Hendriks, Carina Bartelink-Clements, Nellie Nieuwenhuizen, Eric Rovers, Tristan Gallenne, Robert Doornbos, Lex Bakker, Ton Logtenberg, John de Kruif, Piet Gros, Cecile Geuijen, and Mark Throsby. Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.